| Bioactivity | α-HNJNAc is a potent, competitive hexosaminidases inhibitor without interfering with other glycosidases[1]. |
| Invitro | α-HNJNAc (10, 100µM) shows no effect on GM00737 and GM01426 cell lines, but some effect on GM02931 cell line with a significant 1.8 fold activity increase. a-HNJNAc (100µM; 3 days) has no toxicity on human HL60 cell proliferation[1]. NAGLU is inhibited more efficiently by a-HNJNAc (67 µM) than by the uncorrectly configured b-HNJNAc (374 µM)[1]. |
| Name | α-HNJNAc |
| CAS | 1417906-42-3 |
| Formula | C9H18N2O5 |
| Molar Mass | 234.25 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sha Zhu, et al. Iminosugar C-Glycosides Work as Pharmacological Chaperones of NAGLU, a Glycosidase Involved in MPS IIIB Rare Disease. Chemistry. 2021 Aug 5;27(44):11291-11297. |